Soaring Eagle Acquisition in an 8-K filing today said it had achieved a quorum for the Sept. 14 shareholders meeting, having already received enough proxies in support of the SPAC’s proposed merger with Ginkgo.
While shareholders may still change their votes up to the meeting date, Soaring Eagle in the filing said it expects the deal to be approved.
If so, Ginkgo Bioworks stock and warrants would begin trading Sept. 17 on the NYSE under DNA and DNA.WS.
The deal values the combined company at at a $15 billion pre-money equity valuation and is expected to provide up to $2.5 billion of primary proceeds. Led by former MGM CEO Harry Sloan, Soaring Eagle raised $1.5 billion in a February IPO. The SPAC also has PIPE commitments for $775 million. Read more.
